title: Effects of itopride hydrochloride and ranitidine in patients with functional dyspepsia: comparison between prokinetic and acid suppression therapies.
abstract: OBJECTIVE
  The effect of itopride hydrochloride or ranitidine on the health-related quality of life (HRQoL) of functional dyspepsia is not well known. Our aim was to assess the HRQoL before and after administration of itopride hydrochloride or ranitidine in patients with functional dyspepsia.
  
  
  METHODS
  A total of 18 functional dyspepsia patients (12 women, 6 men; mean age 52.5 y.o.) were enrolled. We determined the HRQoL using two different inquiry systems: the 36 item short form of the Medical Outcome Study Questionnaire (SF-36) and the Gastrointestinal Symptom Rating Scale (GSRS). The HRQoL was determined before administration of drug, and two, four, and eight weeks after administration of drug.
  
  
  RESULTS
  After administration of itopride hydrochloride, the SF-36 mental health scale and GSRS indigestion syndrome score and constipation syndrome score were significantly improved compared to before administration (p < 0.05). After the administration of ranitidine, the GSRS reflux syndrome score was significantly improved compared to before administration (p < 0.05).
  
  
  CONCLUSIONS
  Itopride hydrochloride would be useful for the treatment of dysmotility-type functional dyspepsia, whereas ranitidine would be beneficial for ulcer-type functional dyspepsia.
authors.affiliation: First Department of Internal Medicine, Iwate Medical University, Morioka, Iwate, Japan. toschiba@iwate-med.ac.jp
authors.forename: Toshimi
authors.initials: T
authors.lastname: Chiba
authors.forename: Yumi
authors.initials: Y
authors.lastname: Tokunaga
authors.forename: Keisei
authors.initials: K
authors.lastname: Ikeda
authors.forename: Ryo
authors.initials: R
authors.lastname: Takagi
authors.forename: Raita
authors.initials: R
authors.lastname: Chishima
authors.forename: Torahiko
authors.initials: T
authors.lastname: Terui
authors.forename: Norihiko
authors.initials: N
authors.lastname: Kudara
authors.forename: Masaki
authors.initials: M
authors.lastname: Endo
authors.forename: Masaaki
authors.initials: M
authors.lastname: Inomata
authors.forename: Seishi
authors.initials: S
authors.lastname: Orii
authors.forename: Kazuyuki
authors.initials: K
authors.lastname: Suzuki
mesh_terms: D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000008:administration & dosage*; D001549:Benzamides / Q000008:administration & dosage*; D001593:Benzyl Compounds / Q000008:administration & dosage*; D004415:Dyspepsia / Q000188:drug therapy*; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D011788:Quality of Life; D011899:Ranitidine / Q000008:administration & dosage*; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
chemical_list: D000897:Anti-Ulcer Agents; D001549:Benzamides; D001593:Benzyl Compounds; C102254:itopride; D011899:Ranitidine